Thomas Seyfried, PhD, is a professor of biology at Boston College who specializes in the metabolic origins and treatment of cancer. He is the author of "Cancer as a Metabolic Disease" and co-developed the Glucose Ketone Index. His published research focuses on ketogenic metabolic therapy, mitochondrial metabolic theories of cancer, cellular fermentation mechanisms, and repurposed drug combinations for conditions such as glioblastoma.
Cancer cells drive dysregulated growth through the fermentation of glutamine via substrate-level phosphorylation in the mitochondrial matrix.
"one of the mechanisms to drive dysregulated cell growth is the fermentation of glutamine. That's why you have to go back before you can talk about mebendazole, fenbendazole, and some of these others. You have to know how we made the second major discovery after Otto Warburg, which was the fermentation of an amino acid in the matrix of the mitochondria through substrate-level phosphorylation." (said at 0:11:18)
The claim accurately describes the mitochondrial metabolic theory of cancer articulated by Thomas Seyfried and colleagues, which posits that cancer cells utilize glutamine-driven mitochondrial substrate-level phosphorylation (specifically via the succinate-CoA ligase step in the TCA cycle within the mitochondrial matrix) as a fermentation mechanism to generate ATP and drive dysregulated growth when oxidative phosphorylation is impaired. However, the evidence base for this concept consists primarily of theoretical narrative reviews and in vitro preclinical experiments in glioma cell lines, rather than definitive evidence across broad human clinical malignancies.
In a Greek clinical trial of 18 glioblastoma patients receiving standard radiation, those who followed a calorie-restricted Mediterranean diet had significantly improved survival and a higher rate of reaching the three-year mark.
"Even in even in our Greek trial where we had 18 patients, those individual, they were all nuked. And I hate to say it, but that's what they do... But those individuals that did a a calorie-restricted Mediterranean diet lived significantly longer. More of them made the three-year mark than the ones who didn't take the Mediterranean diet." (said at 0:52:00)
The speaker appears to be referring to a 2024 Greek clinical study of 18 patients with glioblastoma (PMID 40041752), but misidentifies the intervention. The study tested dietary ketogenic metabolic therapy (a ketogenic diet), not a calorie-restricted Mediterranean diet. In that prospective cohort of 18 patients, 6 patients adhered to the ketogenic diet for >6 months and exhibited a significantly higher 3-year survival rate compared to the 12 non-adherent patients (66.7% vs. 8.3%, p = 0.0114). However, the evidence certainty is very low due to the tiny sample size, lack of randomization, and inherent selection/adherence bias (e.g., immortal time and healthier-patient bias in those able to adhere). Furthermore, a separate cohort study specifically assessing Mediterranean-like diets in glioblastoma found no survival benefit (PMID 40690185).
- context: Successful application of dietary ketogenic metabolic therapy in patients with glioblastom… (Frontiers in nutrition 2024)
"A total of 18 patients with GBM, 8 women and 10 men, aged between 34 and 75 years participated in a prospective study, examining the impact of ketogenic diet on tumor progression... Among the 18 patients participating in the study, 6 adhered to the ketogenic diet for more than 6 months... Consequently, the survival rate among these patients is 4 out of 6, or 66.7%. Of the 12 patients who did not adhere to the diet, only one reached 36 months of survival, while the rest have died in an average time of 15.7 ± 6.7 months, with a 3-year survival rate of 8.3%. Comparing the survival rates of the two groups, we see that the difference is 58.3% (66.7% versus 8.3%) and is statistically significant with p < 0.05 (0.0114)" (abstract, results)
pubmedfull study (doi) - contradicts: Dietary habits in relation to outcome and therapy-related toxicity in patients with gliobl… (Journal of neuro-oncology 2025)
"We used a 35-item food frequency questionnaire to calculate a dietary score based on Mediterranean-like diet recommendations... Median survival was worse in the higher score group (16.6 vs. 19.4 months, p = 0.004), confirmed by multivariable cox regression analysis (HR 1.60, 95% CI 1.04-2.46; p = 0.034)." (abstract, results)
pubmedfull study (doi)
The majority of dementia cases stem from mitochondrial dysfunction rather than rare inherited genetic mutations.
"the majority of dementia is the result of mitochondrial dysfunction. I mean, there are we all have rare inherited mutations that will be, uh, risk factors for a very few number of people. Most people with dementia are from from abusing mitochondria in one way or another." (said at 1:05:58)
The speaker correctly notes that rare, deterministic inherited genetic mutations account for only a small minority of dementia cases (e.g., autosomal dominant mutations in APP, PSEN1, and PSEN2 account for roughly 1% to 5% of Alzheimer's disease cases, with ~95% classified as sporadic). However, framing the majority of cases as definitively 'stemming from' mitochondrial dysfunction simplifies a complex, multifactorial etiology. While mitochondrial impairment and oxidative stress are recognized as prominent early pathophysiological features—and form the basis of the 'mitochondrial cascade hypothesis'—sporadic dementia arises from a complex combination of advanced aging, polygenic susceptibility (such as APOE alleles and dozens of GWAS risk loci), vascular changes, neuroinflammation, and proteopathy rather than a proven sole origin in mitochondrial failure.
- context: The Alzheimer's disease mitochondrial cascade hypothesis: an update. (Experimental neurology 2009)
"Our hypothesis assumed sporadic and autosomal dominant AD are not etiologically homogeneous, considered evidence that AD pathology is not brain-limited, and incorporated aging theory. The mitochondrial cascade hypothesis asserted: (1) inheritance determines mitochondrial baseline function and durability; (2) mitochondrial durability influences how mitochondria change with age; and (3) when mitochondrial change reaches a threshold, AD histopathology and symptoms ensue." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: Alzheimer's Disease: An Updated Overview of Its Genetics. (International journal of molecular sciences 2023)
"The dominant familial or autosomal presentation represents 1-5% of the total number of cases. It is categorized as early onset (EOAD; <65 years of age) and presents genetic mutations in presenilin 1 ( PSEN1 ), presenilin 2 ( PSEN2 ), or the Amyloid precursor protein ( APP ). Sporadic AD represents 95% of the cases and is categorized as late-onset (LOAD), occurring in patients older than 65 years of age." (abstract, results)
pubmedfull study (doi) - context: Molecular Mechanisms Underlying Alzheimer's Disease Pathogenesis: Comprehensive Overview. (International journal of molecular sciences 2026)
"The vast majority of AD cases are sporadic, with aging representing the primary non-modifiable risk factor contributing to disease susceptibility and progression. However, several factors encompassing genetic predisposition, systemic inflammation, chronic diseases, infections, traumatic brain injury, lifestyle factors, and environmental exposures may affect AD onset." (abstract, results, passage verified)
pubmedfull study (doi)
Paleolithic humans and traditional populations rarely experienced chronic diseases or cancer, dying primarily from infant mortality, infections, and injuries.
"You have to go back and look at our paleolithic ancestors uh or people who live on the planet today according to the traditional ways. They rarely if ever have any chronic diseases or cancer. Uh most of it is injuries and infections. People always say, well, they didn't live long enough. Paleolithic man 300,000 200,000 years ago didn't live long. What are you talking Infant mortality was what was largely killing those people. Infections and injuries. They weren't dying from type 2 diabetes." (said at 1:06:15)
Studies of modern traditional subsistence populations (such as the Tsimane forager-horticulturalists) demonstrate remarkably low rates of chronic cardiometabolic conditions (such as coronary atherosclerosis, hypertension, and type 2 diabetes), with infectious diseases and inflammatory burden predominating. However, extending these findings to all Paleolithic humans and claims of extremely rare cancer requires nuance, as paleopathological detection of cancer is limited by fossil preservation, smaller older-age demographic fractions, and diagnostic constraints.